Purpose: To determine the tolerability and efficacy of ABT-751, an oral antimitotic agent that inhibits polymerization of microtubules, in patients with advanced taxane-refractory non-small cell lung carcinoma (NSCLC). Patients and Methods: Eligibility was limited to patients with recurrent or metastatic NSCLC who had received one to two cytotoxic chemotherapy regimens, had a performance status of zero to one, and adequate organ function. Treatment included ABT-751 200 mg daily for 21 consecutive days, followed by 7 days off drug. Objectives were to determine response rate, time to tumor progression, survival, and tolerability of ABT-751. Results: All 35 enrolled patients were assessable for survival, response, and tolerability. Median time to tumor progression and overall survival were 2.1 and 8.4 months, respectively. The objective response rate was 2.9%. One patient achieved a partial response that was ongoing 567 days after initial documentation. Treatment was well tolerated; fatigue, constipation, and dehydration were the only treatment related, grade three adverse events occurring in more than one patient. Incidence of grade 3/4 hematologic and blood chemistry toxicities was acceptable, and ABT-751 was not associated with myelosuppression. Conclusions: ABT-751 associated toxicity was acceptable. The median time to progression and overall survival as demonstrated for ABT-751 were comparable to other agents considered active in this patient population and to current treatments approved for secondline NSCLC. The novel antimitotic targeting of ABT-751 in combination with the compound's acceptable nonmyelosuppressive toxicity profile and efficacy similar to agents currently in use in this setting, warrant further evaluation of this compound in combination with other cytotoxic agents in advanced NSCLC.
N on-small cell lung carcinoma (NSCLC) comprises 80% of all lung cancers, 1 which are the second most common cancer and the leading cause of cancer mortality in the United States. For patients with distant disease at diagnosis, the prognosis is poor with a 5-year survival rate of 2%. 1 Standard treatment options for stage IV NSCLC consist of chemotherapy and biologic therapies, whereas for stage IIIB, combination with radiotherapy may be indicated. 2, 3 First-line chemotherapies include cisplatin or carboplatin in combination with paclitaxel, docetaxel, gemcitabine, vinorelbine, or irinotecan. 3, 4 Approved second-line therapies include single-agent docetaxel, pemetrexed, and erlotinib. None of these regimens has emerged as superior in the second-line setting, and patients with advanced NSCLC who have failed treatment with one or more chemotherapy regimens currently have limited therapeutic options.
Antimitotic agents are commonly used in the treatment of advanced NSCLC. Three classes of antimitotic agents have been identified. These include vinca alkaloids (e.g., vincristine, vinblastine, and vinorelbine), taxanes (e.g., paclitaxel and docetaxel), and colchicine site binders (e.g., ABT-751). The vinca alkaloids and colchicine site binders inhibit microtubule polymerization by binding to distinct sites on tubulin ␤-subunits, 5 whereas the taxanes block depolymerization by stabilizing microtubules. 6, 7 These actions block the cell cycle at the G2/M phase resulting in the induction of apoptosis.
ABT-751 is a novel, orally bioavailable, sulfonamide antimitotic agent, which has demonstrated antitumor activity in vivo in syngeneic and human xenograft tumor models of colon, lung, breast, pancreas, and bladder cancer. 8 Antitumor activity has occurred with administration of ABT-751 in combination with chemotherapeutic agents such as 5-fluorouracil, cisplatin, docetaxel, and gemcitabine in these respective xenograft models. 8 Moreover, ABT-751 is not a substrate for the multiple drug resistance transporter and demonstrates activity against cell lines resistant to vinca alkaloids and taxanes. 9 ABT-751 has been evaluated in four phase I studies in the United States and one in Japan. 10 -13 In both adult and pediatric patients, ABT-751 demonstrated rapid ab-sorption and elimination, and dose proportional time independent pharmacokinetics across the dose ranges studied with minimal accumulation after multiple once daily and twice daily doses. 10, 11 Common toxicities in both adult and pediatric patients were abdominal pain, fatigue, constipation, and neuropathy.
Differences in the mechanism of antimitotic activity between ABT-751 and the taxanes (i.e., inhibition of polymerization of microtubules by ABT-751 versus depolymerization by taxanes) as well as its resistance to P-glycoprotein mediated transport (which confers cellular resistance to taxane therapy) suggest that ABT-751 might be of therapeutic benefit to patients with advanced taxane refractory NSCLC.
PATIENTS AND METHODS

Patient Selection
Enrollment was limited to patients with measurable, histologically confirmed, stage III B or stage IV NSCLC refractory to taxane therapy. Taxane refractory was defined as a minimum previous taxane exposure of two cycles (i.e., 6 weeks) with disease progression occurring either during taxane therapy, within 12 weeks of completion of therapy in the adjuvant setting, or within 24 weeks of completion of therapy in the metastatic setting. Eligible patients were at least 18 years of age; had an Eastern Cooperative Oncology Group performance status of 0 to 1; had received no more than two prior chemotherapy regimens and no more than one investigational agent, and had discontinued any prior therapy within 3 weeks of ABT-751 administration.
The protocol was approved by the Institutional Review Boards of all participating investigational sites. Voluntary written informed consent was obtained from all patients before performing any study specific procedures or modifying medications to comply with the protocol.
Treatment
Outpatients self-administered ABT-751 200 mg capsules by mouth once daily for 21 consecutive days, followed by 7 days off drug (one cycle ϭ 28 days). The recommended phase II dose was chosen based on observed preclinical activity and Phase I maximum tolerated dose studies. 10 -13 In preclinical modeling, the once daily dosing schedule demonstrated efficacy equivalent to the twice daily dosing schedule in Calu-6 and HT29 xenografts, as well as in the higher dose ranges in the M0576 model. However, QD dosing of ABT-751 was shown to be superior to the BID dosing schedule in the M0576 model at lower doses and in the HT1376 bladder xenograft model at all dose levels. In study M01-303, a phase I solid tumor study, the maximum tolerated dose of 200 mg of ABT-751 administered QD when compared with the maximum tolerated dose of 100 mg of ABT-751 administered BID on a 21 of 28 day schedule demonstrated equivalent tolerability and efficacy.
Toxicity and treatment compliance were graded at each study visit, which occurred every 2 weeks during the first two cycles and before the first dose for each additional cycle. Study drug administration was held for any subject who experienced a National Cancer Institute Common Toxicity Criteria (NCI CTC) grade three or four toxicity that the investigator considered possibly or probably attributable to ABT-751 and not to the underlying disease, until the toxicity resolved to grade 2 or lower. If a cycle was interrupted because of toxicity, and the subject missed six or fewer doses within the 21-day dosing period, the subject resumed the same cycle by taking ABT-751 at a dosage reduced by 50 mg after the toxicity resolved. If the subject missed more than six planned doses within a cycle, that cycle was discontinued and treatment was reinitiated when toxicity resolved with a 50 mg dose reduction of ABT-751. If the toxicity did not resolve, the subject was discontinued from the study drug. To assess treatment compliance, subjects were instructed to return all drug containers, even if empty, to the site study coordinator. The number of capsules returned was recorded on the subject drug accountability log.
Evaluations
Tumor assessments, based on computed tomography scans or magnetic resonance imaging scans, were conducted within 14 days before the initial dose of ABT-751 and subsequently after every two cycles. Toxicities were graded at each study visit according to the NCI CTC (version 3.0). Toxicities not captured by the NCI CTC were categorized as grade 1 (mild), grade 2 (moderate), grade 3/4 (severe, incapacitating, or life-threatening), or grade 5 (death) by the investigator. Hematology and chemistry laboratory tests were performed at baseline and every 2 weeks through the first two cycles, and on day 1 for all subsequent cycles.
Response Criteria
Tumor response and disease progression were determined using the Response Evaluation Criteria in Solid Tumors (RECIST). 14 Assignment of complete response (CR) or partial response (PR) required confirmation of changes in tumor measurements by repeat assessments performed at least 4 weeks after the criteria for response were initially met.
Pharmacokinetic Studies
Blood samples (5 mL each) were obtained on days 1 and 15 of cycle 1 before dosing and 2 hours after dosing. Plasma concentrations of ABT-751 and its major metabolites were measured using a validated liquid chromatography with tandem mass spectrometric detection methodology at Abbott Laboratories (Abbott Park, IL). 11
Statistical Methods
The primary objective of this study was to determine the objective tumor response rate (PRs and CRs according to RECIST) in patients with stage IIIB or IV taxane refractory NSCLC following treatment with ABT-751. Calculation of sample size was based on the assumption that the true objective response rate would be 10%. Thus, with enrollment of 30 patients, the probability that none of the 30 patients would have an objective response was less than 5%.
Analyses of baseline patient characteristics, efficacy, and safety were performed for all enrolled patients. The primary efficacy end point was the objective response rate (ORR). Secondary efficacy endpoints included the time to tumor progression (TTP), overall survival, and the change from baseline to the final visit in Eastern Cooperative Oncology Group performance status.
The ORR was defined and calculated as the percentage of patients with a CR or PR based on RECIST criteria. The 90% confidence interval (CI) was constructed using the exact binomial distribution.
Overall survival was calculated from the date of first dose of ABT-751 to the date of death. All events of death were included, regardless of whether the event occurred while the patient was still taking study drug or after the patient had discontinued study drug. In the absence of death, data were censored at the date of the last study visit, the last contact date, or the date the patient was last known to be alive, whichever was last. Survival was assessed at 3-month intervals after termination of ABT-751 for 2 years. KaplanMeier methodology was used to determine the distributions and 95% CIs for the median and 6-and 12-month rate estimates of TTP and overall survival. 15 Safety was assessed based on ABT-751 exposure, toxicities, deaths, clinical laboratory variables, and vital sign measurements. Toxicities were summarized using the Medical Dictionary for Regulatory Activities (version 9.0), for coding adverse events (AEs). Hematology and blood chemistry toxicities were assigned according to the NCI CTC (version 3.0).
RESULTS
Patient Characteristics and Disposition
Between September 2003 and January 2006, 35 patients with taxane refractory advanced NSCLC were enrolled in this study at 11 investigational sites. Patient characteristics are summarized in Table 1 . Before enrollment, patients had been treated with a median of three oncology agents. The median time from the completion of previous therapy to the start of study drug was 40 days (range, 22-405 days). All patients (100%) had prior taxane therapy, with 22 (63%) receiving paclitaxel and 22 (63%) receiving docetaxel; 9 (26%) patients received both agents. Prior chemotherapy with alkylating agents was reported by 97% (carboplatin in 32 patient [91%], cisplatin in 4 patients [11%]), antimetabolite therapy in 11 patients (31%), and hormones in 1 patient (3%). Nine patients (26%) progressed during taxane therapy. Most patients had prior platinum therapy; 32 (91%) received carboplatin; and 4 (11%) received cisplatin. Ten patients (29%) had prior radiation therapy to the lung or a site of metastatic disease. (8 [23%] ). One patient (3%) was lost to follow-up. Of the patients listed with an AE as reason for study discontinuation, 5 (14.3%) considered AE as being the primary reason for study discontinuation, and 8 (22.9%) as a contributory factor. Of the 5 patients who discontinued study drug for AEs as the primary reason, the treating physician felt the AE to be related to study drug in only 2 cases (grade 3 hallucinations and grade 1 hypotension). Additional AEs listed as contributory reasons for study drug discontinuation were dyspnea, muscle weakness, dizziness, neuropathy, elevated mood, disorientation, constipation, dehydration, weakness, cough, and malaise; of which most were deemed not related to study drug administration. Of the 29 patients who discontinued because of disease progression as the primary reason, 24 met RECIST criteria and 5 discontinued based on clinical judgment. Only one of the five patients who discontinued because of disease progression as a contributory reason met RECIST criteria for progressive disease.
Toxicity and Discontinuation of Study Drug
After discontinuation from the study, 17 subjects (48.5%) went on to receive additional therapeutic regimens for the treatment of their progressive disease. The number of additional therapeutic regimens ranged from 1 to 5 with 5 receiving vinorelbine, 4 given pemetrexed, 5 given gemcitabine, 2 given erlotonib and gefitinib, and 1 each receiving docetaxel, capecitabine, irinotecan, triapine, carboplatin, and halichondrin B.
Exposure to ABT-751
A median of two cycles (range, 1-26 cycles) of ABT-751 was administered, corresponding to a median duration of treatment of 42 days (range, 6 -546 days). Of eight patients (23%) who received less than two cycles of treatments, 3 discontinued because of an AE and 5 discontinued because of progressive disease. RECIST criteria for disease progression were met for 2 b Other includes 9 patients with poorly differentiated carcinoma, 5 patients with carcinoma, and one patient with a large cell undifferentiated tumor. of these 5 patients, whereas disease progression was based on clinical assessments for the remaining 3 patients. Seven patients (20%) received 4 cycles, 2 patients (6%) received 5 cycles, and 1 patient each (3%) received 6, 8, 10, and 26 cycles of ABT-751. Eight patients required a single-dose reduction, and no patients required two-dose reductions.
There were a total of 125 cycles of study drug administered to the 35 patients enrolled on trial. In 113 of the 125 total cycles administered, treating physicians noted a compliance level of Յ80%. This was demonstrative of 90.4% overall study drug compliance through the trial.
Efficacy
Efficacy endpoints are summarized in Table 2 . One patient (3%) achieved a PR after six cycles of treatment. The PR was ongoing at the final tumor assessment, which was 567 days after the initial documentation of PR. A second patient achieved tumor reduction at cycle 2 that was not confirmed per RECIST criteria on a second scan. For this patient, subsequent assessments of stable disease continued through cycle 8, when disease progression occurred. Five patients (14.3%) achieved stable disease, and progressive disease was documented in accordance with RECIST criteria for 25 patients (71%). There were four patients (11.4%) with insufficient data to assess response due to bone only disease. The ORR was 2.9% (90% CI, 0.15-12.85%). The disease control rate (i.e., percentage of patients with CR ϩ PR ϩ stable disease) was 14.2% through cycle 4, 9% through cycle 6, and 6% through cycle 8.
The median TTP was 2.1 month (95% CI, 1.7-3.7 months) (Figure 1 ). The respective 6-and 12-month TTP rate estimates (95% CI) were 14.2% (0.0 -28.4%) and 4.7% (0.0 -13.7%).
Median overall survival was 8.4 months (95% CI, 3.8 -11.4 months) (Figure 2 ). The respective 6-and 12-month survival rate estimates (95% CI) were 56.0% (39.4 -72.7%) and 21.9% (7.6 -36.1%). Data are not sufficiently mature to provide an estimate of survival at 2 years.
Safety and Tolerability
The most commonly experienced treatment related AEs included fatigue (18 patients, 51%), constipation (14 patients, 40%), nausea (12 patients, 34%), and anorexia (10 patients, 29%). Treatment-related grade 3 AEs reported for more than one patient included fatigue (6 patients, 17%) and constipation and dehydration (3 patients each, 9%). Treatmentrelated, grade 4 AEs of laryngeal edema were reported for a single patient (Table 3) .
The incidence of treatment related grade 3 and 4 hematologic and chemistry toxicities was low. The only grade 3 hematologic toxicities that were judged related to ABT-751 were one case each of anemia and lymphopenia. Increased blood alkaline phosphatase, which was the only grade 3 or 4 chemistry toxicity judged related to ABT-751, occurred in a patient with grade 2 elevations in alkaline phosphatase at baseline. All chemistry toxicities were grade 3, except for RECIST, response evaluation criteria in solid tumors. a Tumor assessments were not performed after baseline. hypercalcemia, which was grade 4. In most cases, the abnormal hematology and chemistry values were sporadic and resolved on subsequent testing; in some cases, however, they were the final laboratory value so the time course of resolution remains unknown. Deaths for 29 patients (83%) have been reported to date. Overall, 28 patients died due to progressive NSCLC, and one patient died because of respiratory failure 206 days after the last dose of ABT-751.
Plasma Concentrations of ABT-751 and Its Major Metabolites
Plasma concentrations of ABT-751, ABT-751 glucuronide, and ABT-751 sulfate on days 1 and 15 are summarized in Table 4 . Plasma concentration measurements are available for 30 patients. These results are consistent with data from 21 patients receiving ABT-751 200 mg once daily in two phase I studies.
DISCUSSION
Treatment of patients with advanced NSCLC remains a challenge. Chemotherapy provides limited benefit in the firstline setting, and once disease progression occurs, median survival time is approximately 3 months. Approximately 25 to 50% of patients with advanced NSCLC receive second-line treatment. 16 The median age for diagnosis is 68 years and rising, suggesting that underlying comorbidities and use of concurrent medications might limit the ability to administer and/or tolerate chemotherapy. 4 The limited success rate with currently available agents highlights the need to focus on developing novel agents that are efficacious as well as tolerable.
In this phase II study, ABT-751 administered as secondor third-line therapy in a population of patients with advanced NSCLC refractory taxanes demonstrated an overall survival comparable to that of approved, marketed agents. Median overall survival in this study was 8.4 months, which is comparable to median overall survival reported for docetaxel (range, 6 -9 months) [17] [18] [19] and pemetrexed (8.3 months) in the second-line setting. 20 ABT-751 yielded median overall survival times comparable to those seen in the second-or third-line setting with erlotinib (approximately 7 months), 21 and it is longer than median overall survival seen with best supportive care or placebo (approximately 5 months) in this patient population. 21, 22 Progression-free survival in this study was 2.1 month, which is similar to that seen with erlotinib (2.2 months). 21 The ORR of 2.86% represented a single responder with a confirmed PR ongoing 567 days after initial documentation. The PR was preceded by six cycles of stable disease, suggesting that the time to onset of response with ABT-751 may be delayed. Extended stable disease before a documented objective response is characteristic of the activity of ABT-751. Response rates for drugs used in the second-line setting are comparable. Studies of docetaxel demonstrated an ORR that ranged from 5 to 11%, 17, 18, 20 whereas an ORR of 9% was reported for pemetrexed in one phase III study. 20 It is noteworthy that these efficacy findings for ABT-751 were observed in a more heavily pretreated patient population than those evaluated in studies of single-agent docetaxel and pemetrexed.
ABT-751 is well tolerated and has a unique toxicity profile noteworthy for its lack of myelosuppression. This may be particularly advantageous in conducting combination studies with this agent. There is a need for nonmyelosuppressive agents that can combine with other effective agents whose dose-limiting toxicity is myelosuppression. The most com- mon AEs seen with ABT-751 reflect gastrointestinal system disorders and general disorders. Constipation, fatigue, and dehydration were the most frequent treatment related grade 3 AEs, whereas hematologic and blood chemistry toxicities were uncommon. This is different from currently approved second-line therapies, which have toxicity profiles that include myelosuppression, anemia, rash, and diarrhea.
ABT-751 pharmacokinetics in this study were consistent with those observed in phase I studies. 10, 11 Blood samples were obtained 2 hours after dosing, which corresponds to T max as determined in phase I studies. The concentrations of ABT-751 and its metabolites measured at 2 hours after dosing and before dosing in this study are consistent with C max and C trough as reported previously. 11 Comparison of concentrations of ABT-751 and its metabolites at 2 hours after dosing on days 1 and 15 suggest that there is no systemic accumulation of drug. Clinical pharmacokinetic data suggest that a 200 mg daily dose can achieve an average steady-state area under the curve of approximately 43 g/h/mL, which is in the range of the projected target efficacious plasma exposure (23-70 g/h/mL) as determined in preclinical models.
Based on its lack of myelosuppression, its mechanism of antimitotic action with a unique binding site on ␤-tubulin, and the fact that it is not a substrate for the multiple drug resistance transporter, ABT-751 is a prime candidate for the treatment of cancer. In addition, these properties are ideal for use in combination with other chemotherapeutic agents. Currently, ABT-751 is being evaluated as second-line therapy in combination with docetaxel or pemetrexed in two randomized, placebocontrolled phase II studies in patients with advanced NSCLC and in combination with docetaxel in a study in patients with metastatic hormone-refractory prostate cancer.
